Coronavirus Update: Lilly’s Antibody Plus Remdesivir Trial Abandoned
Other Lilly and NIH Studies Continue
Combination of antibody therapy and Gilead's Veklury fails to show potential in patients with advanced disease.
You may also be interested in...
The price of the antibody monotherapy for COVID-19 will be $1,250 per vial for wealthy countries. CEO David Ricks outlined the company's guidelines for pricing and distributing a limited supply.
After its historic first emergency approval, analysts at Bernstein has upgraded predictions for Pfizer/BioNTech's COVID-19 vaccine in 2021 and beyond.
The big winners of the night were AstraZeneca and Roche as pharma, biotech and allied industries came together online on 2 December to celebrate during a ceremony hosted by Ed Balls.